Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates

This article was originally published on Nasdaq

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.